Answers are grounded in this paper and cite their sources.
Prospective observational study reports the design to predict BCG therapy response in high-risk bladder cancer using rs61094339, suggesting a path toward precision oncology.
Although intravesical Bacillus Calmette-Guérin (BCG) instillation remains the standard of care for patients with highest-risk non-muscle-invasive bladder cancer (NMIBC), nearly 30% of such cases experience disease progression despite adequate treatment. We have identified a single nucleotide polymorphism (SNP), rs61094339 on the X chromosome, which correlates with BCG response. A diagnostic kit based on this SNP was newly developed to stratify patients by their likelihood of response to intravesical BCG therapy. This PRECISE-BCG study is a multicenter, prospective, observational study enrolling 120 patients with histologically confirmed highest-risk NMIBC scheduled for intravesical BCG therapy. Peripheral blood will be collected prior to BCG initiation for genotyping using the rs61094339 SNP kit (KUBIX Inc.). Patients will undergo standard BCG induction (6 weekly instillations) and maintenance therapy (3 weekly instillations at 3, 6, 12, and 18 months) with 2 years of follow-up. The primary endpoint is event-free survival by SNP genotype; secondary endpoints include progression-free survival, intravesical recurrence-free survival, and overall survival. Expected outcome. This study will prospectively validate the predictive performance of a novel SNP-based assay for BCG response. If successful, this kit could provide a precision-medicine tool to guide individualized therapy for NMIBC and identify candidates for early radical cystectomy or novel treatments.
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: